AGI Therapeutics PLC operates in the Commercial physical research sector. AGI Therapeutics Plc (AGI) is a specialty pharmaceutical company. It is focused on the development and commercialization of differentiated specialty drug products to treat unmet medical needs, including conditions which qualify for Orphan drug status. Its products are Rezular (AGI-003), which is an orally administered multiple-mechanism intestinal regulator for the treatment of chronic diarrhea symptoms, particularly those associated with altered gut motility; AGI-010 is a dual modified release capsule containing both delayed and controlled release beads; AGI-006, which is for the treatment of a number of gastro-intestinal and related conditions; AGI-022 is a new once-daily oral form of aminosalicylic acid (ASA), the primary anti-inflammatory drug class used as first-line therapy for the treatment of ulcerative colitis (UC), and AGI-004 is a controlled release transdermal patch for the treatment of non-functional diarrhea conditions, including chemotherapy induced diarrhea (CID). In our complete report available for purchase the company is compared to: Syntopix Group Plc, Lifecycle Pharma A/S and Accelerator Nordic Ab.